Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine

American Journal of Managed Care

Volumn 2, Issue 10, 1996, Pages 1407-1416

  Adelman, James U ^a   Sharfman, Marc ^b   Johnson, Rodney ^c   Miller, David ^a   Clements, Bill ^a   Pait, D Gayla ^a   Gutterman, Donna ^a   Batenhorst, Alice ^a  

^a Adelman Headache Center   (United States)

^b Headache and Neurol Treatm Inst   (United States)

^c Glaxo Wellcome Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344949447     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Solomon GD. Quality-of-life assessment in patients with headache. Pharmacoeconomics 1994;6:34-41.
2. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-343.
3. Dahlof C. Assessment of health-related quality of life in migraine. Cephalalgia 1993;13:233-237.
4. Stang PE, Osterhaus JT. Impact of migraine in the United States: Data from the National Health Interview Survey. Headache 1993;33:29-35.
5. Pryse-Phillips W, Findlay H, Tugwell P, et al. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension-type headache. Can J Neurol Sci 1992;19:333-339.
6. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource use and lost labor costs of migraine headache in the United States. Pharmacoeconomics 1992;2:67-76.
7. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Pharmacoeconomics 1994;28:659-664.
8. Lipton TB, Stewart WF. Migraine in the United States: A review of epidemiology and health care use. Neurology 1993;43(suppl 3):S6-S10.
9. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the Medical Outcomes Study Instrument. Headache 1994;34: 143-147.
10. de Lissovoy G, Lazarus SS. The economic cost of migraine: Present state of knowledge. Neurology 1994;44 (suppl 4):S56-S62.
11. Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology 1995;45(suppl):5-9.
12. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology 1995;45(suppl):10-14.
13. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: Clinical findings. Neurology 1995;45(suppl):15-20.
14. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991; 31:300-305.
15. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-313.
16. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1-96.
17. Ware JE. SF-36 Health Survey: Manual and interpretation guide. Boston, MA: New England Medical Center; 1993.
18. Ware JE, Sherbourne CD. The MOS-36-ltem Short-Form Health Survey (SF-36). Med Care 1992;30:473-483.
19. Miller DW, Kirchdoerfer LJ, Shepherd MD, et al. A disease-specific instrument to measure quality of life effects attributable to migraine. Poster presented at the 10th annual meeting of the Health Services Research Association; June 27-29, 1993; Washington, DC.
20. Mushet GR, Miller DW, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996;36:137-143.
21. Luciani RJ, Osterhaus JT, Gutterman DL. Patient preferences for migraine therapy: Subcutaneous sumatriptan compared with other medications. J Fam Pract 1995;41: 147-152.
22. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: Humanistic, economic, and clinical consequences. Fam Med 1996;28:171-177.
23. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449-454.
24. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm 1996;53:633-638.
25. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated health care costs. Am J Man Care 1996;2:139-143.
26. Lipton RB, Stewart WF. Health-related quality of life in headache research. Headache 1995;35:447-448.